1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Cell and Gene Therapy (CGT) Access Model is sponsored by Department of Health And Human Services. The Cell and Gene Therapy (CGT) Access Model aims to improve the lives of people with Medicaid living with rare and severe diseases by increasing access to potentially transformative treatments. It is a multi-year, voluntary model for states and manufacturers to test whether a CMS-led approach to developing and administering outcomes-based agreements (OBAs) for cell and gene therapies increases Medicaid beneficiaries’ access to innovative treatment, improves their health outcomes, and reduces health care costs and burden to state Medicaid programs. The initial focus of the model is on access to gene therapy treatments for people living with sickle cell disease, a genetic blood disorder. Manufacturers and state participants joined the model through a Request for Application (RFA) process. States begin participation between January 2025 and January 2026.
The Notice of Funding Opportunity (NOFO) announced the opportunity to apply for Cooperative Agreement funding to support states’ participation in the CGT Access Model. Cooperative Agreement funding is intended to support state model implementation activities and to support states that take steps to improve equitable access to gene therapy and multi-disciplinary, comprehensive care in conjunction with the model test. This listing is currently active. Program number: 93.885. Last updated on 2026-01-15.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants are States, the District of Columbia, and any U.S. Territory participating in the Medicaid Drug Rebate Program (MDRP). Eligible applicants must: • Apply to the State Request for Applications (RFA) by no later than March 14, 2025 • Apply to the Notice of Funding Opportunity (NOFO) by no later than March 14, 2025 • Sign a State Agreement with CMS by no later than June 1, 2025 Eligible applicant types include: U.S. State Government (including the District of Columbia), U.S. Territory (or Possession) Government (including freely-associated states), State. Confirm the full requirements in the official notice before applying.
The current listing shows recent federal obligations suggest $5,332,710 (2026). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Yes — Cell and Gene Therapy (CGT) Access Model is offered by Department of Health And Human Services and this listing comes from SAM.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
This opportunity targets applicants in District of Columbia. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Research Infrastructure Programs - Research Centers is sponsored by Department of Health And Human Services. The Office of Research Infrastructure Programs (ORIP), within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director, supports extramural biomedical research by strengthening the infrastructure that enables scientific discovery. ORIP advances human health by fostering the development of critical research models, biomaterials, and technologies; expanding access to state-of-the-art instrumentation and facilities; supporting education and training programs; and assisting small businesses in translating innovative technologies. Through its two divisions, the Division of Comparative Medicine (DCM) and the Division of Construction and Instruments (DCI), ORIP plays a critical role in accelerating biomedical research nationwide. DCM develops and sustains essential research models and biological resources, manages the infrastructure required for their use and distribution, and provides training to ensure investigators have reliable access to high-quality models and facilities. DCI supports shared, cost-effective access to advanced scientific instrumentation, modernizing research facilities, and providing critical equipment that enables transformative biomedical discoveries. Together, DCM and DCI strengthen U.S. competitiveness and ensure the biomedical research community has the infrastructure necessary to address emerging health challenges, prevent disease, promote health, and advance foundational science. This listing is currently active. Program number: 93.3RC. Last updated on 2026-01-28.
Research Infrastructure Programs - Construction is sponsored by Department of Health And Human Services. The Office of Research Infrastructure Programs (ORIP), within the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director, supports extramural biomedical research by strengthening the infrastructure that enables scientific discovery. ORIP advances human health by fostering the development of critical research models, biomaterials, and technologies; expanding access to state-of-the-art instrumentation and facilities; supporting education and training programs; and assisting small businesses in translating innovative technologies. Through its two divisions, the Division of Comparative Medicine (DCM) and the Division of Construction and Instruments (DCI), ORIP plays a critical role in accelerating biomedical research nationwide. DCM develops and sustains essential research models and biological resources, manages the infrastructure required for their use and distribution, and provides training to ensure investigators have reliable access to high-quality models and facilities. DCI supports shared, cost-effective access to advanced scientific instrumentation, modernizing research facilities, and providing critical equipment that enables transformative biomedical discoveries. Together, DCM and DCI strengthen U.S. competitiveness and ensure the biomedical research community has the infrastructure necessary to address emerging health challenges, prevent disease, promote health, and advance foundational science. This listing is currently active. Program number: 93.CN1. Last updated on 2026-01-28.
The STOMP program funds measurement tools and removal therapies for microplastics in human tissue. Proposals due June 22. Eligibility, phases, and strategy.
Read articleThe Gates Foundation committed at least $1 billion over two years to equitable AI alongside its 10th Goalkeepers Report — 40% education, 40% health, 10% agriculture, 10% digital infrastructure. Five days later, 60 organizations signed a five-year goal to reach 3.4 billion speakers of underrepresented languages. Here is how implementing nonprofits should read both.
Read articleThe Health and Extreme Weather highlighted topic went live September 1, 2026 with eleven awarding institutes and expires May 1, 2028. There is no set-aside, no separate deadline, and no review criteria — which makes the institute-by-institute language the only real signal, and it is not uniform.
Read article